Allergy and asthma proceedings :
-
Allergy Asthma Proc · Sep 2018
Randomized Controlled Trial Multicenter StudySeasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
Benralizumab is a humanized, afucosylated, monoclonal antibody that targets interleukin-5 receptor alpha and induces direct, rapid, and nearly complete depletion of eosinophils via enhanced antibody-dependent cell-mediated cytotoxicity. In the United States, benralizumab is indicated for add-on maintenance treatment of patients ≥12 years old with severe asthma and an eosinophilic phenotype. ⋯ Benralizumab significantly and consistently reduced asthma exacerbations across all seasons versus placebo for patients with severe, uncontrolled eosinophilic asthma.
-
Allergy Asthma Proc · Mar 2016
Randomized Controlled TrialSQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis.
Allergy immunotherapy is a treatment option for allergic rhinoconjunctivitis (ARC). It is unique compared with pharmacotherapy in that it modifies the immunologic pathways that elicit an allergic response. The SQ Timothy grass sublingual immunotherapy (SLIT) tablet is approved in North America and throughout Europe for the treatment of adults and children (≥5 years old) with grass pollen-induced ARC. ⋯ Therefore, the SQ grass SLIT-tablet has an indication as a disease-modifying therapy in Europe, and a sustained effect is recognized in the United States.
-
Allergy Asthma Proc · Mar 2014
Randomized Controlled Trial Multicenter StudyBronchodilator effect of single-dose formoterol administered by pressurized metered-dose inhaler in children with asthma aged 6 to <12 years receiving budesonide.
Dose-response of formoterol via pressurized metered-dose inhaler (pMDI) has not been determined in asthmatic pediatric patients aged 6 to <12 years. This study was designed to assess the bronchodilating dose-response of three formoterol pMDI doses in children with stable asthma aged 6 to <12 years receiving twice-daily (b.i.d.) budesonide 160 micrograms. A U. ⋯ Formoterol pMDI showed generally dose-proportional pharmacokinetics to 9 micrograms, as determined by urinary excretion. Single doses of formoterol pMDI showed a dose-response, with formoterol 9 micrograms exhibiting a maximum response, in pediatric patients aged 6 to <12 years with persistent stable asthma maintained on b.i.d. budesonide pMDI 160 micrograms. Clinical trial NCT01136655, www.clinicaltrials.gov.
-
Allergy Asthma Proc · Nov 2012
Randomized Controlled Trial Comparative StudyEffect of epinephrine autoinjector design on unintentional injection injury.
Epinephrine is an essential medication for the treatment of anaphylaxis. Factors associated with autoinjector design may have a role in its correct use. We compared a new and old epinephrine autoinjector with respect to correct autoinjector use. ⋯ Significantly fewer participants had unintentional injections in the new compared with the old epinephrine autoinjector group (p < 0.001). When all assessment steps are considered, only the rate of placing a wrong tip into the outer thigh was significantly lower in the new compared with the old epinephrine autoinjector group (p < 0.05). The new epinephrine autoinjector is more effective in unintentional injection injuries than the old one; however, it still does not fulfill the criteria of an ideal epinephrine autoinjector.
-
Allergy Asthma Proc · Jul 2011
Randomized Controlled TrialResponse to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials.
Hereditary Angioedema (HAE) is a rare, debilitating, genetic disorder characterized by acute attacks of edema without urticaria. Ecallantide, a direct plasma kallikrein inhibitor, is approved for treatment of acute HAE attacks. This article addresses the efficacy of ecallantide in the treatment of moderate-to-severe attacks of HAE based on time to treatment. ⋯ For overall response, complete or near-complete resolution was greatest within the 0- to 2-hour cohort (71.4%). As with other therapies for HAE early ecallantide therapy is optimal. Treatment with ecallantide within 6 hours of symptom onset leads to more rapid and sustained improvement of symptoms.